Pfizer buys gene therapy company - Is it a good investment?

Rare Disease Report. James Radke, PhD, Published Online: Monday, Aug 01, 2016

Pfizer has acquired gene therapy company Bamboo Therapeutics for a deal that could be worth up to $645 million.
Bamboo therapeutics is developing gene therapy for Giant Axonal Neuropathy (GAN) that is currently in phase 1/2 trial. The company also has gene therapies in development for 3 other neuromuscular diseases – Duchenne muscular dystrophy, Canavan, and Friedreich’s ataxia.

  Pfizer buys gene therapy company - Is it a good investment?